Articles by Emily Menendez
Tislelizumab is a monoclonal antibody with a high affinity and binding specificity against programmed cell death protein 1.
SBRT with sorafenib is shown to be associated with a clinically important but not statistically significant improved OS rate.
A recent study utilized patient data from 13 medical centers in a biomarker analysis of 1L ICIs with & without ...
A recent observational study determined if there is a correlation between the improvement of ADR and lower rates of CRC.
The designation is based on positive results from an ongoing collaborative trial between GSK and MSK Cancer Center.
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
The GAP system was found to predict actionable genetic alterations including FGFR2 and IDH.
Campylobacter bacteria have been found to be enriched in primary CRC lesions of patients with metastasis.
The phase 3 KEYNOTE-177 study compared the efficacy of pembrolizumab with chemotherapy for the treatment of MSI-H/dMMR mCRC.
The survival rate benefit increased over time for patients treated with TTFields, with a 13% improvement in OS at 12 months.
A blood-based, non-invasive classifier can serve as an optional tool for conventional methods in the detection of NETs.
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
HERIZON-BTC-01 marks the largest phase IIb clinical trial to date for patients with previously treated HER2-positive disease.
A recent systematic review evaluated the relationship between NLR and the prognosis of patients who receive NAC.
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
Studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
In several different types of cancer, tumor budding is linked to poor survival outcomes.
The SOX chemotherapy regimen for gastric cancer consists of S-1, an oral fluoropyrimidine, in combination with oxaliplatin.
Repeated use of TACE can impair liver function and stimulate tumor angiogenesis.
While biliary tract cancer is one of the fastest-growing types of early-onset cancers, little is known about its biology.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.